C4 Therapeutics, Inc. (CCCC) earnings date
Feb 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | before open | 42 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | before open | 37 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "1 C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027" exhibit |
| Q3 FY2026 | "Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide with Elranatamab; Progressing Additional Cohorts with Data from All Evaluated Cohorts Expected in Mid-2027 Phase 1b Trial of Cemsidomide in Combination with Approved Standard of Care Multiple Myeloma Therapies On Track to Initiate in 1H 2027 WATERTOWN, Mass., November 5, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the third quarter ended Sep" exhibit |
| Q3 FY2026 | "With data expected from these trials in 2027, we believe next year will be pivotal in establishing cemsidomide’s therapeutic profile and its potential to address the significant unmet need of patients with multiple myeloma across an evolving standard of care.”" exhibit |
| Q3 FY2026 | "Data from all evaluated cohorts are expected in mid-2027." exhibit |
| Q3 FY2026 | "A trial-in-progress poster featuring the Phase 1b design for the trial evaluating cemsidomide in combination with elranatamab in RRMM will be presented at the 68th American Society of Hematology Annual Meeting taking place from December 12 - 15, 2026, in New Orleans, Louisiana." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology Association (EHA) 2026 Congress Further Support Cemsidomide’s Potential Best-in-Class Profile in Multiple Myeloma Phase 1b Trial of Cemsidomide in Combination With Approved Standard of Care Multiple Myeloma Therapies On Track to Initiate in 1H 2027 WATERTOWN, Mass., August 11, 2026 (G" exhibit |
| Q2 FY2026 | "Together, these studies are expected to generate clinical milestones in 2027 and beyond and will support our vision of establishing cemsidomide as a potential backbone therapy for combination regimens in multiple myeloma.”" exhibit |
| Q2 FY2026 | "The ongoing Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in late-line multiple myeloma (MM) treatment is on track to complete enrollment in the first quarter of 2027." exhibit |
| Q2 FY2026 | "The initial investigator-assessed overall response rate (ORR) data are expected in the second half of 2027." exhibit |
| Q2 FY2026 | "C4T expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CCCC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CCCC
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CCCC/"><img src="https://veritasdata.dev/embed/CCCC.svg" alt="CCCC earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CCCC/)
Script
<script async src="https://veritasdata.dev/embed/CCCC.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CCCC"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.